PATENT CLAIM ANALYSIS

Application Number: 16242315
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "253070"]

Abstract:
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Claim (Index 43):
The composition of  claim 42  wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 99.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14252907', '10540577', '15176464', '10556600', '14639797']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8034048596528318
- 35 USC 102 Novelty (BERT): 0.5725335488254892
- Combined Prediction Score: 0.7803177285700975
- Mean Citation Score: 471.90887200000014
- Max Citation Score: 566.6824
- Similarity Product: 316.55993982787135

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test